While the results of these trials have shown various degree of efficacy in improving histopathology features (i.e. steatohepatitis, ballooning and fibrosis) of NASH and biochemical efficacy in reducing AST/ALT levels, none of these agents has been able to completely reverse NASH features, while side effects have emerged. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.